Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in …
…, CP Crispino, KV Smirnakis, MG Emery… - Journal of the American …, 2012 - jacc.org
Objectives : The aim of this study was to evaluate the safety, tolerability, and effects of AMG
145 on low-density lipoprotein cholesterol (LDL-C) in healthy and hypercholesterolemic …
145 on low-density lipoprotein cholesterol (LDL-C) in healthy and hypercholesterolemic …
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease
MG Emery, JM Fisher, JY Chien, ED Kharasch… - Hepatology, 2003 - Elsevier
Previous studies suggest that hepatic cytochrome P450 2E1 (CYP2E1) activity is increased
in individuals with chronic alcoholism, nonalcoholic steatohepatitis (NASH), and morbid …
in individuals with chronic alcoholism, nonalcoholic steatohepatitis (NASH), and morbid …
[HTML][HTML] Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor
S Kasichayanula, A Grover, MG Emery… - Clinical …, 2018 - Springer
Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density
lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. …
lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. …
Reprint: Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in …
…, MS Moxness, MH Ma, MG Emery… - Toxicologic …, 2007 - journals.sagepub.com
Recombinant human glial cell line-derived neurotrophic factor (r-metHuGDNF) is a potent
neuronal growth and survival factor that has been considered for clinical use in the treatment …
neuronal growth and survival factor that has been considered for clinical use in the treatment …
Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (S)-2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino) …
…, RW Hungate, K Gahm, MG Emery… - Journal of medicinal …, 2010 - ACS Publications
Thiazolones with an exo-norbornylamine at the 2-position and an isopropyl group on the 5-position
are potent 11β-HSD1 inhibitors. However, the C-5 center was prone to epimerization …
are potent 11β-HSD1 inhibitors. However, the C-5 center was prone to epimerization …
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model
…, M Kerschnitzki, WJ Sasiela, MG Emery… - European Heart …, 2022 - academic.oup.com
Aims Many patients are unable to achieve guideline-recommended LDL cholesterol (LDL-C)
targets, despite taking maximally tolerated lipid-lowering therapy. Bempedoic acid, a …
targets, despite taking maximally tolerated lipid-lowering therapy. Bempedoic acid, a …
Impact of target‐mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 …
…, M Kuchimanchi, A Grover, MG Emery… - The Journal of …, 2017 - Wiley Online Library
Understanding the pharmacokinetic (PK) and pharmacodynamic (PD) relationship of a
therapeutic monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) …
therapeutic monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) …
The disposition and metabolism of bempedoic acid, a potent inhibitor of ATP citrate lyase, in healthy human subjects
…, C Cramer, D MacDougall, MG Emery - Drug Metabolism and …, 2023 - ASPET
The disposition and metabolism of bempedoic acid, a selective inhibitor of ATP citrate lyase,
were examined in healthy male subjects. After a single administration of [ 14 C] bempedoic …
were examined in healthy male subjects. After a single administration of [ 14 C] bempedoic …
Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans
MG Emery, C Jubert, KE Thummel… - Journal of Pharmacology …, 1999 - ASPET
Disulfiram (DSF) is a mechanism-based inhibitor of cytochrome P-450 2E1 (CYP2E1),
resulting in loss of CYP2E1 protein and activity, which may be useful in preventing CYP2E1-…
resulting in loss of CYP2E1 protein and activity, which may be useful in preventing CYP2E1-…
[HTML][HTML] Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects …
…, RL Crass, S Chapel, WJ Sasiela, MG Emery - … of Pharmacokinetics and …, 2023 - Springer
Population pharmacokinetics (popPK) of bempedoic acid and the popPK/pharmacodynamic
(popPK/PD) relationship between bempedoic acid concentrations and serum low-density …
(popPK/PD) relationship between bempedoic acid concentrations and serum low-density …